---
schema_version: "secwatch.filing_event.v1"
accession: "0001568651-24-000004"
form_type: "8-K"
ticker: "OSCR"
cik: "0001568651"
company_name: "Oscar Health, Inc."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T06:57:28.819687+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Oscar Health posts FY2023 net loss $271M; 2024 adjusted EBITDA guidance positive $125M-$175M

## Summary
- FY2023 Direct and Assumed Policy Premiums $6.6B (-3% YoY); Premiums earned $5.7B (+47% YoY).
- Medical Loss Ratio improved 370 bps to 81.6%; InsuranceCo Combined Ratio 99.5% (640 bps improvement).
- Net loss $271M improved $339M YoY; Adjusted EBITDA loss $45M improved $417M YoY.
- Membership 1,036,283 as of Dec 31, 2023, down from 1,151,483 a year ago.
- 2024 guidance: Total Revenue $8.3B-$8.4B; MLR 80.2%-81.2%; Adj. EBITDA $125M-$175M (positive).

## SEC filing metadata
- accession: 0001568651-24-000004
- form_type: 8-K
- ticker: OSCR
- cik: 0001568651
- company_name: Oscar Health, Inc.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1568651/000156865124000004/0001568651-24-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1568651/000156865124000004/oscr-20240207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001568651-24-000004
- JSON: https://secwatch.observer/filing/0001568651-24-000004.json
- Plain text: https://secwatch.observer/filing/0001568651-24-000004.txt

## Key facts
- Earnings Releases
  Oscar Health, Inc. reported Fiscal Year Ending December 31, 2024 results: revenue $8,300,000 to $8,400,000. Guidance initiated.
  - Period: Fiscal Year Ending December 31, 2024
  - Revenue: $8,300,000 to $8,400,000
  - Guidance: initiated
  - Result: guidance update
  source text: The Company anticipates Total Revenue of $8.3 billion to $8.4 billion, a Medical Loss Ratio of 80.2% to 81.2%, a SG&A Expense Ratio of 20.5% to 21.0%, and Total Company Adjusted EBITDA of $125 million to $175 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1568651/000156865124000004/0001568651-24-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.